Search

Join us for our upcoming webinar

• Webinar

Retina UK is delighted to have awarded a new three-year research grant to Prof Majlinda Lako at Newcastle University for a project entitled: To establish AAV.PRPF31 gene augmentation in PRPF31-deficient RPE and photoreceptor cells and assess its efficacy in restoring RPE and photoreceptor function.

• News
• Retinitis pigmentosa

Our monthly e-Newsletter featuring the latest updates from Retina UK. Subscribe now to receive these updates directly to your email.

• e-Newsletter
• Audio
• Written

Including a gift to Retina UK in your Will is an incredibly special way to help our vital work continue into the future.

In 2014 we funded an exciting new collaborative project. The UK Inherited Retinal Dystrophy Consortium (UKIRDC) Project brought together the four largest research groups in the UK specialising in inherited retinal diseases (IRDs).

During our 50th anniversary year, Retina UK was the focus of a BBC Lifeline Appeal on Sunday 16 November 2025.

Luxturna, a gene therapy, is only for the treatment of Leber congenital amaurosis type 2 (LCA2) and severe early-onset RP caused by mutations in a specific gene called RPE65.

• FAQ
• Written

Biopharmaceutical company ProQR is conducting a Phase 2/3 clinical trial (Illuminate) to measure the safety and effectiveness of RNA therapy, Sepofarsen which aims to treat Leber's Congenital Amourosis (LCA) 10.

• News
• Leber congenital amaurosis (LCA)

Research determines that taking high dose vitamin A supplements does not slow vision loss in people with retinitis pigmentosa (RP).

• News

Our monthly e-Newsletter featuring the latest updates from Retina UK. Subscribe now to receive these updates directly to your email.

• e-Newsletter
• Audio
• Written